Merck, a science and technology company, completed the acquisition of Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology. Financial terms were not disclosed. “We look forward to joining Merck and are confident that our expertise in bioprocessing process development will complement the Mobius® portfolio and help advance life-enhancing therapeutics,” Michael Chiu, Erbi Biosystems President and CEO.